

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**ALPHAMAB ONCOLOGY**

**康寧傑瑞生物製藥**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 9966)**

## **VOLUNTARY ANNOUNCEMENT**

### **COLLABORATION WITH ARRIVENT IN RELATION TO THE RESEARCH, DEVELOPMENT AND COMMERCIALIZATION OF ADC PRODUCTS**

This announcement is made by Alphamab Oncology (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on June 5, 2024, Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (“**Alphamab**”), a wholly-owned subsidiary of the Company, entered into a research and collaboration agreement (the “**Collaboration Agreement**”) with ArriVent BioPharma, Inc., the shares of which are listed on the Nasdaq Global Market (ticker symbol: AVBP) (“**ArriVent**”).

According to the terms of the Collaboration Agreement, Alphamab and ArriVent will collaborate to use Alphamab’s proprietary linker-payload (Alphatecan) and glycan-conjugation platforms to discover and develop novel antibody drug conjugates (“**ADC**”). Alphamab will retain the rights to develop and commercialize the related ADC products (the “**ADC Products**”) under the Collaboration Agreement, in mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan Region (collectively, the “**Greater China Region**”). ArriVent will have exclusive rights to develop and commercialize the ADC Products in the field of oncology in countries and regions outside of the Greater China Region and will be responsible for and bear the cost of the corresponding development of the ADC Products. According to the Collaboration Agreement, Alphamab is entitled to receive a one-time, non-refundable upfront payment and potential milestone payments based on the achievement of certain regulatory, development, and sales milestones of up to US\$615.5 million in aggregate for the programs. In addition, Alphamab is also entitled to receive tiered sales royalties from ArriVent for each ADC Product.

## **ABOUT ARRIVENT**

ArriVent is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. ArriVent seeks to utilize its team's deep drug development experience to maximize the potential of its lead development candidate, firmonertinib, and advance a pipeline of novel therapeutics, such as next-generation ADCs, through approval and commercialization.

## **ABOUT THE COMPANY**

The Company is a leading biopharmaceutical company in China with a fully integrated proprietary biologics platform in bispecific and protein engineering. The Company's highly differentiated in-house pipeline consists of monoclonal antibodies, bispecific antibodies, and ADCs in staggered development status in oncology, including, among others, one approved for marketing by the National Medical Products Administration of China and three in late clinical stage. The Company has developed various technologies and platforms of antibody-based therapies for oncology treatment and expertise in this regard. Benefitting from the proprietary protein engineering platforms and structure-guided molecular modeling expertise, the Company is able to create a new generation of multi-functional biological drug candidates that could potentially benefit patients globally.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited:** The Company cannot guarantee that it will be able to develop and/or ultimately market the ADC Products successfully. Shareholders and potential investors of the Company are advised to exercise due care when dealing in the shares of the Company.

By Order of the Board  
**Alphamab Oncology**  
**Dr. XU Ting**  
*Chairman and Executive Director*

Hong Kong, June 5, 2024

*As at the date of this announcement, the Board comprises Dr. XU Ting as the chairman of the Board and executive Director and Ms. LIU Yang as executive Director, and Dr. GUO Zijian, Mr. WEI Kevin Cheng and Mr. WU Dong as independent non-executive Directors.*